Amphastar Pharmaceuticals, Inc.
AMPH
Rank in Stocks
#7739
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho... Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Share Price
$29.38
Last synced: 2026-11-09
Market Cap
$1.25B
Change (1 day)
3.12%
Change (1 year)
8.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Amphastar Pharmaceuticals, Inc. (AMPH)
Category
Healthcare
EPS for Amphastar Pharmaceuticals, Inc. (AMPH)
EPS as of September 2026 TTM: $2.25
According to Amphastar Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $2.25. At the end of 2025 the company had an EPS of $2.10, a decrease compared to its 2024 EPS of $3.29.
EPS history for Amphastar Pharmaceuticals, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $2.25 | 7.14% |
| 2025 | $2.10 | -36.17% |
| 2024 | $3.29 | 15.44% |
| 2023 | $2.85 | 51.60% |
| 2022 | $1.88 | 44.62% |
| 2021 | $1.30 | 4,262.42% |
| 2020 | $0.03 | -97.13% |
| 2019 | $1.04 | -966.67% |
| 2018 | $-0.12 | -220.00% |
| 2017 | $0.10 | -56.52% |
| 2016 | $0.23 | -470.97% |
| 2015 | $-0.06 | -75.20% |
| 2014 | $-0.25 | -116.89% |
| 2013 | $1.48 | -34.51% |
| 2012 | $2.26 | 132.99% |
| 2011 | $0.97 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 188.95% |
DE
|
|
| $6.08 | 170.12% |
DE
|
|
| $1.55 | -31.08% |
JP
|
|
| $3.66 | 62.67% |
CH
|
|
| $0.45 | -80.00% |
IL
|
Questions about Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS)?
Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $2.25, as of Sep 2026.
What was Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS) was $2.10, 36.17% less than in 2024 ($3.29).
How has Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS) went from $0.03 to $2.10, an average growth of 133.89% a year.
How does Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Amphastar Pharmaceuticals, Inc.'s earnings per share (EPS) ($2.25) is higher than that of 2 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.